

TALK BY DR PHILIP E HARRIS

12TH NOVEMBER 2018



Dr Philip E Harris
BSc MB BCh PhD FRCP
FRSB

TARGETED RADIONUCLIDE THERAPY IN PRECISION ONCOLOGY

Philip E Harris was appointed Chief Medical Officer of ITM Isotopen Technologien München AG in June 2018. He is responsible for providing clinical leadership to ITM's radiopharmaceutical development platform. With more than 16 years of leadership experience in industry, Philip has contributed greatly to the development of various theranostic radionuclide therapy platforms in oncology. His previous industry positions include Director of Global Medical Affairs at Pharmacia, Senior Director of Clinical Development at Pfizer, and Vice President at Ipsen. Philip is a distinguished clinical endocrinologist and general physician, with a strong academic background. Prior to moving into industry, he held an academic consultant appointment at King's College Hospital, London in internal medicine and adult endocrinology.

Philip was trained in endocrinology at the University of Wales College of Medicine, at St Bartholomew's Hospital, London, The University of Newcastle-upon-Tyne and Massachusetts General Hospital, Boston. He holds a Bachelor of Medicine & Surgery and a PhD from the University of Wales.

WHEN:

Monday, 12 November 2018
5.30pm – 7.00pm

WHERE:

Seminar Room L1-S4, Level 1
Academia, SGH Campus
20 College Road, Singapore 169856
Max Capacity: 80pax

REGISTRATION:

Complimentary
RSVP by 5 November 2018

RSVP TO:

secretariat@nmss.org.sg
Or 9105 8697

PROGRAMME

1730hrs	Registration
1800hrs	Welcome Address
1805hrs	Targeted Radionuclide Therapy in Precision Oncology by Dr Philip Harris
1835hrs	Discussion
1900hrs	End of Talk

Organised by



Supported by

